Invixo Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.20 M
- Company Age 7 Year, 10 Months
- Last Filing with ROC 31 Mar 2019
- Revenue Growth 311.64%
- Ebitda 92.36%
- Net Worth 5.94%
- Total Assets 31.32%
About Invixo Pharmaceutical
Invixo Pharmaceutical Private Limited (IPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 10 April 2017 (Seven years and ten months 11 days old ). Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Mustak Bholim and Anees Bholim serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999PN2017PTC169845
- Company No.
169845
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Apr 2017
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Invixo Pharmaceutical?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anees Bholim  | Managing Director | 10-Apr-2017 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mustak Bholim | Director | 10-Apr-2017 | Current |
Financial Performance of Invixo Pharmaceutical.
Invixo Pharmaceutical Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 311.64% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth moved up by a moderate rise of 5.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Invixo Pharmaceutical?
Unlock access to Invixo Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Invixo Systems (Opc) Private LimitedMustak Bholim is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Invixo Pharmaceutical?
Unlock and access historical data on people associated with Invixo Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Invixo Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Invixo Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.